Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 26;14(9):e70009. doi: 10.1002/ctm2.70009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

The co‐location of MMP7+ tumour cells and CD14+APOE+ cells worsen the clinical outcome of non‐small cell lung cancer (NSCLC) patients. (A) The correlation of MMP7 and CD14 in the bulk transcriptomics data. (B) The correlation of MMP7 and APOE in the bulk transcriptomics data. (C) The multiplex immunofluorescence performed in 20 NSCLC patients demonstrated the co‐location of MMP7+ tumour cells and CD14+APOE+ cells in NSCLC tumour area. (D) The distribution of CD14+ cells and CD14+APOE+ cells in areas with high/low MMP7+ tumour cells. (E) MMP7 in tumour cells and APOE in myeloid cells had elevated expression in non‐responders (NR) patients than responders (R). (F) The NR exhibited higher MMP7 compared to responders in NSCLC patients treated with immunotherapy. (G) The NR exhibited higher APOE compared to responders in NSCLC patients treated with immunotherapy. (H) Patients with higher MMP7 had significantly worse therapeutic results. (I) Patients with higher APOE had significantly worse therapeutic results.